Abstract
The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.
Original language | English (US) |
---|---|
Title of host publication | Targeted Therapies for Non-Small-Cell Lung Cancer |
Publisher | Future Medicine Ltd. |
Pages | 47-54 |
Number of pages | 8 |
ISBN (Electronic) | 9781780840468 |
ISBN (Print) | 9781780841236 |
DOIs | |
State | Published - Oct 1 2012 |
ASJC Scopus subject areas
- Medicine(all)